Patient-targeted websites on overactive bladder: What are our patients reading?

Overactive Bladder

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Health Qual Life Outcomes.

Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, Schermer CR

doi: 10.1186/s12955-018-0892-0.

Overactive Bladder

Detection and quantification of overactive bladder activity in patients: Can we make it better and automatic?

Neurourol Urodyn.

Niederhauser T, Gafner ES, Cantieni T, Grämiger M, Haeberlin A, Obrist D, Burkhard F, Clavica F

doi: 10.1002/nau.23357.

Overactive Bladder

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Neurourol Urodyn.

Mueller ER, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Stoelzel M, Yoon SJ, Al-Shukri S, Rechberger T, Gratzke C

doi: 10.1002/nau.23919.

Overactive BladderUrinary Incontinence

Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?

Int Urogynecol J.

Goldman HB, Oelke M, Kaplan SA, Kitta T, Russell D, Carlsson M, Arumi D, Mangan E, Ntanios F

doi: 10.1007/s00192-018-3640-4.

Overactive Bladder

Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sjögren syndrome

Lupus.

Pereira E Silva R, Romão VC, Neves M, Garcia R, Oliveira S, Brites J, Ramos FO, Canhão H, Palma Dos Reis J, Pereira da Silva JA, Lopes T

doi: 10.1177/0961203318811605.

Overactive Bladder

Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial

Patient.

Herdman M, Nazir J, Hakimi Z, Siddiqui E, Huang M, Pavesi M, MacDiarmid S, Drake MJ, Devlin N

doi: 10.1007/s40271-017-0262-8.

Overactive Bladder

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice

Eur Urol.

Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A

doi: 10.1016/j.eururo.2017.01.037.

Overactive BladderUrinary Tract Infections (UTI)

The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis

World J Urol.

Jo JK, Kim KN, Kim DW, Kim YT, Kim JY, Kim JY

doi: 10.1007/s00345-017-2121-6.

Overactive Bladder

International Phase III, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR

J Urol.

Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr

doi: 10.1097/JU.0000000000000807.

Related content

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Detection and quantification of overactive bladder activity in patients: Can we make it better and automatic?

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?

Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sjögren syndrome

Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice

The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis

International Phase III, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR